Purchase this article with an account.
E. S. Lopez, O. J. Croxatto, J. E. Gallo; Suramab Strongly Inhibits Lymphangiogenesis and Angiogenesis in the Cornea. Invest. Ophthalmol. Vis. Sci. 2010;51(13):5694.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To analyze the effect of Suramab and Bevacizumab to inhibit angiogenesis and lymphangiogenesis in the cornea.
Corneal neovascularization was induced in three groups of nine White New Zealand rabbits, applying a filter paper disc soaked in 1M Na (OH) on the central cornea. Group 1 was treated after injury with intravenous Suramab (S) at a doses equivalent to 3mg/kg of Bevacizumab and 10mg/kg of Suramin, Group 2 was treated with intravenous Bevacizumab (B) at a doses of 3mg./kg, and Group 3 did not receive any treatment. Corneal sections were inmunohistochemically analysed with primary antibodies Lyve-1 (lymphatic vascular endothelial marker) and Pecam as an endothelial marker. The jimage program was used to calculate hematological and lymphatic vascularized areas.
The area of immunoreactivity for blood vessels was smaller in treated groups (S: 0.76mm²; B: 0.95 mm²) compared to controls (3.4 mm²) . The area stained with Lyve-1 was significantly reduced in suramab (0.56 mm²) group than that found in Bevacizumab (1.62mm²) and control animals (2.8mm²) (p<0.05).
Intravenous Suramab and Bevacizumab inhibit angiogenesis and lymphangiogenesis in the cornea, although the effect of Suramab is stronger.
This PDF is available to Subscribers Only